Peptide Repertoires of HLA class I molecules

主要组织相容性复合体（MHC）I类分子结合肽抗原， 将这些抗原呈递给CD 8 T细胞。人类MHC I类变异体由 HLA-A、HLA-B和HLA-C基因。这些基因是高度多态的。的 多态性影响许多传染病、癌症和 炎症性疾病。在三个HLA I类基因座中，显示了HLA-B分子， 对多种疾病的结果有显著影响。给定的HLA I类 同种异型可以结合大量的细胞和病原体衍生的肽， 统称为肽组。HLA-B肽段的多样性可能是一个因素 它们对疾病结果的不同影响。许多因素 预测影响HLA I类同种异型之间的肽组多样性，包括 肽结合位点的结构、细胞内组装机制和 肽缺陷形式的内在稳定性。几个HLA-B分子组装在一起， 通过非常规的细胞内途径，这表明存在新的 非常规的表位。我们建议使用液体 色谱-质谱法（LC-MS）定量、表征和 了解所选HLA-B变体的肽段的全部宽度。基于 现有的MS数据集，我们还将开发全球标准化的方法来量化和 比较不同HLA-B变体的肽组差异。这项研究的结果将 对癌症疫苗设计中的表位和HLA选择具有重要意义 和传染病。这些研究还将建立识别新的 疾病相关的表位，并允许更好地了解 HLA I类基因型与疾病结局

Major histocompatibility complex (MHC) class I molecules bind to peptide antigens and present these antigens to CD8 T cells. Human MHC class I variants are encoded by the HLA-A, HLA-B and HLA-C genes. These genes are highly polymorphic. The polymorphisms influence outcomes in a number of infectious diseases, cancers and inflammatory diseases. Among the three HLA class I loci, HLA-B molecules are shown have dominant influences upon outcomes in multiple diseases. A given HLA class I allotype can bind to a large number of cellular and pathogen-derived peptides, collectively called the peptidome. The diversity of HLA-B peptidomes could be one factor underlying their different effects upon disease outcomes. A number of factors are predicted to influence peptidome diversity among HLA class I allotypes, including the structure of the peptide-binding site, the intracellular assembly mechanism and the intrinsic stability of the peptide-deficient form. Several HLA-B molecules are assembled via unconventional intracellular pathways that are suggestive of the presence of novel unconventional epitopes within their peptidomes. We propose to use liquid chromatography mass spectrometry (LC-MS) methods to quantify, characterize and understand the full breadth of the peptidomes of selected HLA-B variants. Based on existing MS datasets, we will also develop globally normalized methods to quantify and compare peptidome diversities of different HLA-B variants. The findings of this study will be significant towards epitope and HLA selection during vaccine design against cancers and infectious diseases. The studies will also establish methods to identify novel disease-relevant epitopes, and allow a better understanding of the relationships between HLA class I genotypes and disease outcomes.